PH12014502794A1 - Prophylactic and/or therapeutic agent for mild cognitive impairment - Google Patents

Prophylactic and/or therapeutic agent for mild cognitive impairment

Info

Publication number
PH12014502794A1
PH12014502794A1 PH12014502794A PH12014502794A PH12014502794A1 PH 12014502794 A1 PH12014502794 A1 PH 12014502794A1 PH 12014502794 A PH12014502794 A PH 12014502794A PH 12014502794 A PH12014502794 A PH 12014502794A PH 12014502794 A1 PH12014502794 A1 PH 12014502794A1
Authority
PH
Philippines
Prior art keywords
prophylactic
therapeutic agent
cognitive impairment
mild cognitive
preparation
Prior art date
Application number
PH12014502794A
Inventor
Ihara Masafumi
Maki Takakuni
Taguchi Akihiko
Original Assignee
Found Biomedical Res & Innov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Found Biomedical Res & Innov filed Critical Found Biomedical Res & Innov
Publication of PH12014502794A1 publication Critical patent/PH12014502794A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided is a prophylactic and/or therapeutic agent for mild cognitive impairment, which can improve interstitial flow in cerebral blood vessels and the like to achieve the sufficient clearance of harmful proteins accumulated in the brain. The prophylactic and/or therapeutic agent comprises 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]3,4- dihydrocarbostyril or a salt thereof as an active ingredient. The prophylactic and/or therapeutic agent can improve the flow of an interstitial fluid around blood vessels in a drainage pathway to excrete harmful proteins. The prophylactic and/or therapeutic agent for mild cognitive impairment according to the present invention may take the form of a preparation for oral administration, a liquid preparation for oral administration, or an injectable preparation. The prophylactic and/or therapeutic agent for mild cognitive impairment according to the present invention can be used for the prevention and/or treatment of cerebral amyloid angiopathy, and can also be used for the amelioration of dementia with Lewy bodies, Down's syndrome or macular degeneration.
PH12014502794A 2012-06-15 2014-12-15 Prophylactic and/or therapeutic agent for mild cognitive impairment PH12014502794A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012135906 2012-06-15
JP2012223580 2012-10-05
US2013003740 2013-06-14

Publications (1)

Publication Number Publication Date
PH12014502794A1 true PH12014502794A1 (en) 2015-02-09

Family

ID=53180441

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12014502794A PH12014502794A1 (en) 2012-06-15 2014-12-15 Prophylactic and/or therapeutic agent for mild cognitive impairment

Country Status (1)

Country Link
PH (1) PH12014502794A1 (en)

Similar Documents

Publication Publication Date Title
SG11201408323RA (en) Prophylactic and/or therapeutic agent for mild cognitive impairment
IL265774B (en) Diagnosis, prevention and treatment of diseases of the joint
PH12015502773A1 (en) Methods for treating or preventing opthalmological conditions
MY171920A (en) Prevention and treatment of ocular conditions
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
WO2013170068A3 (en) Nuclear transport modulators and uses thereof
ME02414B (en) Treatment of crohn's disease with laquinimod
WO2015165413A8 (en) New stable antibody-drug conjugate, preparation method therefor, and use thereof
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
IL233557A0 (en) Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnfa therapy
PL2524693T3 (en) Pharmaceutical for preventing or treating disorders accompanied by ocular angiogenesis and/or elevated ocular vascular permeability
EP3015111A4 (en) Use of chinese medicine preparation in preparing drug for preventing and/or treating crohn's disease
WO2011116020A3 (en) Ophthalmic formulations of cetirizine and methods of use
EP3405159A4 (en) Treatment and prevention of retinal vascular disease by photocoagulation
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
WO2015048188A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
EP2301561A4 (en) Pharmaceutical composition for treatment of dry eye and/or corneal/conjunctival disorders
MX357888B (en) Base addition salts of nitroxoline and uses thereof.
WO2013189606A3 (en) Interval therapy for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
WO2014116015A3 (en) Composition for preventing alzheimer's disease, containing purple bamboo salt, and method for preparing purple bamboo salt
HK1243327A1 (en) Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their formulations, for use in the prevention and/or in the treatment of hyperactivated tissue conditions
WO2014117010A3 (en) Composition for ophthalmic administration
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
PH12014502794A1 (en) Prophylactic and/or therapeutic agent for mild cognitive impairment
WO2013038200A3 (en) Neurodevelopmental disorders